Shanghai No.1 PharmacyLtd's (SHSE:600833) Three-year Earnings Growth Trails the 22% YoY Shareholder Returns
Shanghai No.1 PharmacyLtd's (SHSE:600833) Three-year Earnings Growth Trails the 22% YoY Shareholder Returns
By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with prowess, you can make superior returns. For example, the Shanghai No.1 Pharmacy Co.,Ltd. (SHSE:600833) share price is up 76% in the last three years, clearly besting the market decline of around 15% (not including dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 26% in the last year, including dividends.
通過購買指數基金,您可以輕鬆地大致匹配市場回報。但如果您有能力選擇個別股票,您可以獲得更優的回報。例如,上海第一醫葯股份有限公司(SHSE:600833)的股價在過去三年中上漲了76%,明顯超過了市場下降約15%的水平(不包括分紅派息)。然而,最近的回報並沒有那麼令人印象深刻,這隻股票在過去一年中的回報僅爲26%,包括分紅派息。
Since it's been a strong week for Shanghai No.1 PharmacyLtd shareholders, let's have a look at trend of the longer term fundamentals.
由於上海第一醫葯股份有限公司股東上週表現強勁,讓我們來看一下更長期基本面的趨勢。
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
用本傑明·格雷厄姆的話說:在短期內,市場像個投票機,但在長期內,它就是個稱重機。檢視市場情緒如何隨時間變化的一種方法是觀察一家公司的股價與每股收益(EPS)之間的互動。
During three years of share price growth, Shanghai No.1 PharmacyLtd achieved compound earnings per share growth of 56% per year. This EPS growth is higher than the 21% average annual increase in the share price. Therefore, it seems the market has moderated its expectations for growth, somewhat.
在三年的股價增長中,上海第一醫葯有限公司的每股收益實現了每年56%的複合增長。這個每股收益的增長高於股價平均每年21%的增長。因此,市場似乎對增長的預期有所減緩。
You can see how EPS has changed over time in the image below (click on the chart to see the exact values).
您可以在下面的圖像中查看每股收益隨時間的變化(單擊圖表查看確切值)。

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.
在買入或賣出股票之前,我們總是建議仔細審查歷史增長趨勢,詳情請見這裏。
What About Dividends?
關於分紅派息的問題
It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, Shanghai No.1 PharmacyLtd's TSR for the last 3 years was 82%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!
考慮任何給定股票的總股東回報以及股價回報是很重要的。總股東回報(TSR)包含了任何剝離或折扣融資的價值,以及任何分紅,假設這些分紅被再投資。可以說,對於支付分紅的股票,總股東回報提供了更完整的圖景。實際上,第一醫葯有限公司在過去三年的總股東回報爲82%,超過了之前提到的股價回報。這在很大程度上是由於其分紅支付!
A Different Perspective
不同的視角
It's good to see that Shanghai No.1 PharmacyLtd has rewarded shareholders with a total shareholder return of 26% in the last twelve months. And that does include the dividend. That gain is better than the annual TSR over five years, which is 11%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand Shanghai No.1 PharmacyLtd better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Shanghai No.1 PharmacyLtd (at least 1 which is concerning) , and understanding them should be part of your investment process.
看到第一醫葯有限公司在過去的十二個月內爲股東帶來了26%的總股東回報是件好事。這包括了分紅。這個收益好於五年的年度總股東回報11%。因此,最近對公司的情緒似乎是積極的。考慮到股價動能仍然強勁,仔細看看這隻股票或許值得,以免錯失機會。長期跟蹤股價表現總是很有趣。但爲了更好地了解第一醫葯有限公司,我們需要考慮許多其他因素。例如,投資風險的揮之不去的陰影。我們已經識別出了第一醫葯有限公司的兩個警告標誌(至少有一個是令人擔憂的),理解這些應是您投資過程的一部分。
If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.
如果你像我一樣,那麼你一定不想錯過這份內部人士正在購買的被低估的小型股免費名單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文中引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。